INDEMNIFICATION AGREEMENTIndemnification Agreement • March 14th, 2022 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • Delaware
This Indemnification Agreement (“Agreement”) is made as of _________, 2022 by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ________ (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
FOURTH amendment to LeaseLease • March 14th, 2022 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
THIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the ___8th__day of ____March____________, 2022 (the “Effective Date”), by and between GRE RIVERWORKS, LLC, a Delaware limited liability company (“Landlord”), and EYEPOINT PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 14th, 2022 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
VIA EMAILCommercial Alliance Agreement • March 14th, 2022 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
EyePoint Pharmaceuticals, Inc. (“EyePoint”) and ImprimisRx, LLC (“Imprimis”) entered into a Commercial Alliance Agreement effective as of August 1, 2020, as modified by the Letter Agreement dated November 12, 2020 (collectively, the “Agreement”). Capitalized terms used but not defined in this letter have their respective meanings set forth in the Agreement. All changes to the Agreement described below shall be effective as of January 1, 2022 (the “Expansion Effective Date”). For good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
